Düsseldorf Regional Court grants second-medical use injunctions for Novartis Afinitor cancer treatment By Annsley Merelle Ward on Monday, January 24, 2022 #IPKat AmeriKat breast cancer Dusseldorf Regional Court German patent law Injunction Novartis Opposition Division Second medical use +
Keeping up with Dutch patent litigation: second half-year case law review 2020 By Annsley Merelle Ward on Monday, May 17, 2021 #IPKat AmeriKat biogen cross-border Dutch law eli lilly equivalence Netherlands Novartis patent litigation pemetrexed samsung SPCs the hague +
Never Too Late: if you missed The IPKat last week By Magdaleen Jooste on Sunday, November 01, 2020 #IPKat Art. 53(c) EPC Certification mark cross-border injunction exclusion from patentability Invalidity action mylan Novartis Paediatric Extension +
Hague District Court grants cross-border preliminary injunction against Mylan in Novartis SPC battle By Léon Dijkman on Thursday, October 22, 2020 #IPKat cross-border injunction Léon Dijkman mylan Novartis Orphan drug paediatrix extension preliminary injunction SPC +
SPCs and orphan drugs-- is the double layer getting messy or is it just a matter of timing? A new ruling of the District Court in the Hague to shed some light? By Frantzeska Papadopoulou on Monday, October 19, 2020 Frantzeska Papadopoulou Novartis orphan drugs Paediatric Extension SPC Supplementary Protection Certificate +
UCL IBIL Event: Boris v Corbyn v Trump - putting a price on patents, medicine and innovation By Annsley Merelle Ward on Friday, November 22, 2019 #IPKat AmeriKat compulsory licensing crown use ibil IP and pharma mr justice birss NHS Novartis open access open innovation Teva trade agreement ucl UK politics +
SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19) By Dr Rose Hughes on Friday, June 28, 2019 article 3(c) biologics canakinumab CJEU Ilaris monocolonal antibody Novartis patents pharmaceutical industry Second medical use SPC SPC regulation Supplementary Protection Certificate +
PI awarded following disagreement with EPO on added matter - Novartis v Dr Reddy's By Eibhlin Vardy on Tuesday, January 29, 2019 added matter Afinitor Art 123(2) cross-undertaking Disclosure dr reddy's everolimus Novartis preliminary injunction +
Novartis v. Teva: Patent rivalries meet again, this time on a non-negligible injunction. By Frantzeska Papadopoulou on Friday, June 29, 2018 injunctions Novartis patent infringement pharmaceutical Teva +
No toleration for Novartis - rivastigmine patch patent declared invalid By Darren Smyth on Monday, April 27, 2015 actavis added matter divisional application Focus infringement Novartis obviousness patent Teva validity +